Segmental (Partial) Cystectomy — Bladder-Preserving Surgery for Selected Bladder Cancer — Cost, Top Hospitals & Success Rates | MyMedicPlus

Segmental cystectomy — also called partial cystectomy — is a surgical procedure in which a discrete portion of the bladder wall is excised while the remaining bladder is reconstructed and retained. It is a bladder-preserving alternative to radical cystectomy for a carefully selected minority of patients with muscle-invasive bladder cancer (MIBC) or large benign bladder tumours not amenable to transurethral resection alone.

Bladder cancer is the most common malignancy of the urinary tract. Muscle-invasive bladder cancer (MIBC, T2–T4) traditionally has radical cystectomy as the gold-standard curative surgical option. However, radical cystectomy carries significant morbidity: permanent urinary diversion, sexual dysfunction, wound complications, and a lengthy recovery. In appropriately selected patients, segmental cystectomy can achieve equivalent oncological outcomes while preserving native bladder function, continence, and quality of life.

The procedure was widely practiced in the pre-neoadjuvant chemotherapy era but fell out of favour as the limitations of poor patient selection became apparent — high local recurrence rates in unselected series drove many urologists towards routine radical cystectomy. Contemporary practice, informed by refined selection criteria, intraoperative frozen section analysis, systematic pelvic lymphadenectomy, and the routine integration of neoadjuvant cisplatin-based chemotherapy, has rehabilitated partial cystectomy as a valid and evidence-supported option in the hands of experienced urological oncologists.

Historically, segmental cystectomy has also been performed for large benign lesions — including bladder endometriosis, bladder paragangliomas (phaeochromocytomas), inflammatory masses, and large benign transitional cell papillomas — where the lesion is too large for safe transurethral resection but radical excision is not oncologically necessary. In these benign indications, outcomes are excellent with low recurrence rates.

Segmental cystectomy is considered in the following clinical conditions:

• Muscle-Invasive Bladder Cancer (MIBC) — T2: Urothelial carcinoma invading the muscularis propria (T2) arising as a solitary lesion at the dome, posterior wall, or lateral wall, with no concurrent carcinoma in situ (CIS) elsewhere in the bladder. This is the primary oncological indication where bladder preservation is sought.
• Selected T3 Tumours: In carefully selected patients where perivesical fat involvement is limited and confined to the primary tumour site, T3a disease may be considered for partial cystectomy within a multimodality framework including neoadjuvant chemotherapy. This remains controversial, and most guidelines recommend radical cystectomy for T3+ disease.
• Urachal Carcinoma: Adenocarcinoma arising from the urachal remnant at the bladder dome is a classic and well-accepted indication for segmental cystectomy (en bloc resection of the urachal tract, bladder dome, and umbilicus). Oncological outcomes with this approach are comparable to radical cystectomy for this rare tumour type.
• Large Benign Bladder Tumours: Paragangliomas (functional or non-functional) of the bladder wall, large endometriotic nodules invading the detrusor, inflammatory pseudotumours, and large villous adenomas not amenable to TURBT are appropriate benign indications for segmental resection.
• Bladder Diverticular Tumours: Urothelial carcinoma arising within a bladder diverticulum — which lacks a muscularis propria layer and therefore has a propensity for early extravesical spread — may be managed with segmental cystectomy including diverticulectomy.
• Isolated Bladder Metastasis: Rare cases of isolated secondary tumours involving the bladder wall (e.g., from colorectal cancer, melanoma) without systemic disease spread may benefit from resection for local control.

Rigorous patient selection is the single most important determinant of oncological success with segmental cystectomy. The following criteria define the ideal candidate:

Mandatory Favourable Tumour Characteristics:

• Solitary tumour: Single primary tumour (not multifocal disease, which implies a field cancerisation defect throughout the urothelium and high intravesical recurrence risk).
• Anatomical location: Tumour must be located at the bladder dome, posterior wall, or lateral wall — sites that allow adequate resection margins without compromising the trigone, bladder neck, or ureteric orifices.
• Distance from trigone: The tumour edge must be at least 2 cm from both ureteric orifices and the bladder neck to allow a tumour-free margin without risking ureteric injury or trigonal resection that would necessitate reimplantation or bladder reconstruction.
• Absence of carcinoma in situ (CIS): CIS elsewhere in the bladder is an absolute contraindication to partial cystectomy. Pre-operative mapping biopsies — systematic cold-cup biopsies of the trigone, dome, posterior wall, lateral walls, and prostatic urethra (in males) — must confirm CIS-free urothelium throughout the remainder of the bladder. CIS at distant sites indicates a field effect rendering partial resection oncologically inadequate.
• Technically resectable lesion: The planned resection must be executable with a minimum 2 cm surgical margin around the tumour, leaving sufficient bladder volume for acceptable post-operative function (>150 mL expected capacity).

Diagnostic Prerequisites: Transurethral resection of the bladder tumour (TURBT) must be performed before partial cystectomy to confirm pathological diagnosis, muscle invasion depth, and grade. Staging cross-sectional imaging (CT urogram and chest CT) is mandatory to exclude upper tract disease, nodal involvement (N+), and distant metastasis. Cystoscopy under anaesthesia with systematic mapping biopsies must confirm the absence of CIS or satellite lesions.

The segmental cystectomy procedure integrates several technical components to maximise oncological safety and functional outcomes:

• Surgical Approach — Open: Traditionally performed via a midline or Pfannenstiel laparotomy with extraperitoneal or transperitoneal bladder access. The open approach provides the greatest tactile feedback for margin assessment and is preferred for large or difficult tumours, obese patients, or those with prior pelvic surgery.
• Minimally Invasive Approach (Laparoscopic/Robotic): Robot-assisted laparoscopic partial cystectomy (RALPC) has been demonstrated in selected series to be technically feasible with comparable oncological outcomes to open surgery, offering the benefits of reduced blood loss, shorter hospital stay, and faster recovery. However, widespread adoption is limited by technical complexity and availability of robotic platforms.
• Intraoperative Frozen Section Analysis: After bladder wall excision, frozen section pathological assessment of all resection margins — mucosal, deep, and lateral — is performed intraoperatively. The presence of tumour at any margin mandates further resection or conversion to radical cystectomy. This real-time margin control is the key safety mechanism that distinguishes contemporary practice from historical series with high margin-positive rates.
• Pelvic Lymphadenectomy: Bilateral pelvic lymph node dissection (PLND) is performed concurrently with partial cystectomy in virtually all MIBC cases. Standard template includes the obturator, external iliac, and hypogastric lymph node packets (a minimum of 10–14 nodes). Extended template adds common iliac and presacral nodes. PLND serves dual purpose: accurate pathological nodal staging (upstaging N0 to N+ in 15–20% of clinical N0 patients) and potential therapeutic benefit through removal of micrometastatic disease.
• Neoadjuvant Cisplatin-Based Chemotherapy: In alignment with guidelines for MIBC management, neoadjuvant chemotherapy (NAC) with cisplatin-based regimens (MVAC — methotrexate, vinblastine, doxorubicin, cisplatin; or GC — gemcitabine plus cisplatin) is recommended before partial cystectomy in cisplatin-eligible patients. NAC achieves pathological complete response (pT0) in 25–40% of patients and downstages tumours in an additional 25–30%, potentially converting marginally resectable lesions to clearly resectable ones and treating micrometastatic disease.
• Ureteric Reimplantation: When the tumour or planned resection margin is close to a ureteric orifice, ureteric reimplantation (ureteroneocystostomy) may be required simultaneously. This technical addition increases operative time and complexity but is necessary to achieve adequate margins without sacrificing ureteric function.

In properly selected patients, segmental cystectomy offers a compelling combination of oncological efficacy and quality-of-life preservation:

• Bladder Preservation: The most obvious and patient-valued benefit. Native bladder function — normal voiding, continence, and sexual function — is preserved in the majority of patients without the profound lifestyle impact of permanent urinary diversion (ileal conduit or neobladder). This is particularly important for elderly patients or those with significant comorbidities who may tolerate permanent stoma poorly.
• Oncological Outcomes — 5-Year Overall Survival: Published series of carefully selected patients report 5-year overall survival rates of 50–70%, directly comparable to radical cystectomy in analogously selected patients. A critical caveat is that published results are subject to selection bias — partial cystectomy is performed in patients with the most favourable tumour characteristics, who would also be expected to do better with radical cystectomy. Matched comparison studies show equivalent 5-year cancer-specific survival for patients meeting strict selection criteria.
• Lower Perioperative Morbidity: Compared to radical cystectomy — which involves full cystectomy, prostatectomy or anterior vaginectomy, and urinary diversion — segmental cystectomy carries substantially lower blood loss, shorter operating time, reduced intraoperative complications, shorter hospital stay, and faster return to normal activities.
• Sexual Function Preservation: Radical cystectomy in males results in erectile dysfunction in the majority of patients despite nerve-sparing techniques. Segmental cystectomy does not disrupt the pelvic autonomic nerve plexuses, preserving erectile and ejaculatory function. In females, anterior vaginectomy and ovarian removal performed with radical cystectomy are avoided.
• Staging Information: Concurrent pelvic lymphadenectomy provides accurate nodal staging, which informs prognosis and guides adjuvant therapy decisions.

The principal risks of segmental cystectomy relate to both the inherent limitations of bladder-preserving surgery in a malignant disease and the procedural risks of pelvic surgery:

• Local Tumour Recurrence: The most significant oncological risk. Intravesical recurrence — new urothelial tumours arising elsewhere in the bladder — occurs in 40–60% of patients at 5 years and reflects the field cancerisation defect of urothelial malignancy. Many of these recurrences are non-muscle-invasive and can be managed with transurethral resection and intravesical therapy. However, muscle-invasive recurrence necessitates salvage radical cystectomy.
• Positive Surgical Margins: Despite frozen section analysis, positive margins occur in a minority of cases and are associated with significantly higher local recurrence rates and reduced overall survival. Positive margins require immediate re-excision or conversion to radical cystectomy.
• Need for Salvage Radical Cystectomy: Approximately 20–35% of partial cystectomy patients ultimately require salvage radical cystectomy over the long term due to recurrent invasive disease, rendering bladder preservation a bridge rather than a permanent solution in a proportion of patients.
• Reduced Bladder Capacity: Depending on the extent of bladder wall resected, post-operative bladder capacity may be reduced, resulting in increased urinary frequency and urgency. Physiotherapy and bladder training can partially mitigate these symptoms, and most patients adapt over 3–6 months as the remaining bladder wall distends.
• Pelvic Complications: Standard surgical risks of pelvic surgery apply: bleeding requiring transfusion, urine leak at the bladder closure site, pelvic haematoma or abscess, bowel injury, deep venous thrombosis, pulmonary embolism, and wound complications. Ureteric injury risk is <2% with experienced surgeons.
• Delayed Diagnosis of Synchronous Upper Tract Disease: Synchronous upper tract urothelial carcinoma occurs in 2–4% of MIBC patients; thorough pre-operative urographic imaging is essential to exclude this before committing to bladder preservation.

Post-operative surveillance after partial cystectomy must be intensive and sustained for life, given the significant risk of both intravesical and upper tract urothelial recurrence:

Cystoscopic Surveillance: Rigid or flexible cystoscopy with urine cytology is performed at 3-month intervals for the first 2 years, then every 6 months for years 3–5, then annually thereafter. Any suspicious lesion identified endoscopically undergoes biopsy and/or transurethral resection. The rigour of cystoscopic surveillance is a critical determinant of outcomes — early detection of recurrence enables organ-preserving management where possible.

Upper Tract Surveillance: CT urogram (CTU) or MRI urogram is performed annually to detect upper tract urothelial carcinoma in the ipsilateral and contralateral collecting systems and ureters. This is particularly important given the field cancerisation nature of urothelial malignancy.

Cross-Sectional Imaging for Systemic Disease: CT chest, abdomen, and pelvis is performed at 6 months and 1 year post-operatively, then annually for 5 years, to detect nodal or distant metastatic recurrence. PET-CT may be used in cases of diagnostic uncertainty.

Adjuvant Intravesical Therapy: In patients with pT2 disease at partial cystectomy who did not receive neoadjuvant chemotherapy, or those with non-muscle-invasive recurrence following partial cystectomy, intravesical immunotherapy with BCG (Bacillus Calmette-Guérin) is considered, though its efficacy in the post-partial-cystectomy setting is not as well established as in primary non-muscle-invasive disease.

Quality of Life Assessment: Patient-reported outcomes including urinary function (FACT-Bl, ICIQ-SF), sexual function, and global quality of life are assessed at baseline and annually using validated questionnaires, informing ongoing supportive care needs.

The total cost of segmental cystectomy — including pre-operative neoadjuvant chemotherapy, the surgical procedure, post-operative care, and long-term surveillance — varies substantially by country and healthcare setting:

• Neoadjuvant Chemotherapy: Three to four cycles of gemcitabine-cisplatin (GC) or dose-dense MVAC administered before surgery typically adds USD 15,000–40,000 in the USA (including drug costs, infusion centre fees, and supportive care medications), USD 5,000–15,000 in Western Europe, or USD 1,500–4,000 in India.
• Surgical Procedure — USA: Open partial cystectomy with pelvic lymphadenectomy in an academic US centre costs USD 30,000–75,000 in total hospital and surgeon charges. Robot-assisted laparoscopic partial cystectomy may be higher due to robotic platform fees. Total episode-of-care costs (including 30-day post-discharge) often reach USD 50,000–100,000.
• UK (NHS and Private): Under the NHS, care is free at point of delivery. Private partial cystectomy at a London specialist centre costs approximately GBP 8,000–18,000 for the procedure alone, excluding neoadjuvant chemotherapy and surveillance.
• India: At internationally accredited cancer centres (Tata Memorial, Apollo, AIIMS private wards), partial cystectomy costs approximately USD 3,000–6,000 for the procedure, with total episode costs including neoadjuvant chemotherapy of USD 5,000–12,000. Robotic-assisted approaches are available at major centres for USD 5,000–10,000.
• Thailand and Turkey: Partial cystectomy at major international hospitals in Bangkok or Istanbul costs approximately USD 5,000–12,000 inclusive, representing significant savings compared to UK private or US rates.
• Surveillance Costs: The long-term cystoscopic surveillance burden is an often under-acknowledged cost driver. Annual surveillance costs of USD 2,000–5,000 (flexible cystoscopy with cytology and annual CT) must be factored into long-term cost comparisons with radical cystectomy, which requires similar imaging but less frequent cystoscopic follow-up.

The management of muscle-invasive bladder cancer involves several established alternatives, each with distinct oncological and functional trade-offs:

• Radical Cystectomy (RC): The gold-standard curative surgical procedure for MIBC, involving complete removal of the bladder (and prostate/seminal vesicles in males, or uterus/anterior vaginal wall/ovaries in females) with urinary diversion. RC achieves definitive local disease control with 5-year cancer-specific survival of 60–70% for pT2N0M0 disease. It eliminates the risk of intravesical recurrence entirely but at the cost of permanent urinary diversion and associated quality-of-life impact. RC with neoadjuvant chemotherapy remains the guideline-recommended standard of care for MIBC in patients who are medically fit and anatomically unsuitable for bladder preservation.
• Trimodal Therapy (TMT) — Bladder Preservation Without Surgery: The alternative non-surgical bladder-preserving approach combines maximal TURBT (resection of all visible tumour), concurrent radiosensitising chemotherapy (cisplatin alone or CMV — cisplatin, methotrexate, vinblastine), and definitive external beam radiotherapy to the bladder (64 Gy in 32 fractions). TMT achieves complete response in 60–70% of patients and 5-year overall survival of 50–60% in selected patients — outcomes comparable to radical cystectomy in matched series. TMT is particularly suitable for patients who are medically unfit for radical cystectomy (poor renal function precluding cisplatin, severe cardiovascular disease, or patient preference for non-surgical management). NICE guideline NG2 (bladder cancer) supports TMT as an alternative to cystectomy in appropriately selected patients.
• TURBT Alone (for Low-Volume T2 Disease): For small, solitary, well-differentiated T2 tumours in elderly or medically unfit patients who cannot tolerate either cystectomy or full-course radiotherapy, repeat aggressive TURBT with close endoscopic surveillance is an option, accepting higher local recurrence rates in exchange for avoiding major surgery. This is generally considered palliative rather than curative intent.
• Immunotherapy — Pembrolizumab: For cisplatin-ineligible MIBC patients, pembrolizumab (anti-PD-1) has demonstrated efficacy as first-line therapy. While primarily an alternative to chemotherapy rather than to surgery, pembrolizumab-based neoadjuvant regimens are under active investigation in clinical trials as a prelude to bladder-preserving surgery.